Life sciences is a priority sector for global economies. And Lithuania is emerging as an advanced innovation hub in Central and Eastern Europe. In the country’s well-established research and development scene, researchers and entrepreneurs are actively commercializing science to shape the future of healthcare and beyond.
The sector has grown elevenfold in the last ten years, making it one of the nation’s most valuable. Lithuania has top-level universities, cranking out 5-7 thousand STEM professionals early. And it is teeming with top labs and incubator spaces for biotech startups.

The UK is making €15m investment in its biopharmaceutical manufacturing industry via its national innovation agency Innovate UK. It is part of the country’s larger push to support the domestic Life Sciences.

ETH Zurich researchers have developed a gene switch that triggers insulin release in designer cells by playing music.

British CDMO Oxford Biomedica plc announces the expansion of its License and Supply Agreement with cell therapy specialist Cabaletta Bio, Inc. The new agreements adds CD19 as a new target – it originally covered Cabaletta Bio’s lead product, DSG3-CAART.

Oil-eating bacteria form dendritic biofilms that reshape oil droplets to speed up the rate of consumption

French vaccine maker Valneva SE will double the amount of a US$100m debt financing granted by Deerfield Management Company and OrbiMed.

Basel- and Heidelberg-based CDMO Celonic Group has appointed Dr Samanta Cimitan as Chief Executive Officer (CEO).

Swiss Spexis AG  has announced a US$2.5m capital commitment to fund a two-part pivotal Phase III study to get market approval for its inhaled cystic fibrosis antibiotic colistimethate sodium.

With a US$1bn acquisition of Canadian Inversago Pharma, Novo Nordisk A/S fiights to maintain its dominant position in the booming weight loss drug market.

British researchers have proven that a new gene can prevent progression of hereditary kidney damage in mice.